Senate hearing may be on horizon for HCV drug prices

According to the Wall Street Journal, Gilead may be due at a Senate hearing before year's end to discuss how the cost of new HCV treatments—like Sovaldi and Harvoni—will affect the US Department of Veterans' Affairs. The VA added Sovaldi to its national formulary last March, according to the paper. Senator Bernard Sanders (I-VT), the chairman of the Senate Committee on Veterans' Affairs, plans to hold the hearing to discuss the impact of these drugs on the VA. A spokesperson for the senator told WSJ that the hearing may occur after midterm elections on November 4th.


Next Article in Pharmaceutical